0001437749-20-023535 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 12, 2020
Document Information [Line Items]
Entity Registrant Name	CORETEC GROUP INC.
Entity Central Index Key	0001375195
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		204,950,642
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 23,655	$ 58,149
Prepaid expenses	178,400	88,821
Total current assets	202,055	146,970
Property and equipment, net		126
Other assets:
Patents, net	1,079,083	1,139,255
Goodwill	166,000	166,000
Deposits-other	1,260	3,575
Total other assets	1,246,343	1,308,830
Total Assets	1,448,398	1,455,926
Current liabilities:
Notes payable	69,545	39,138
Accounts payable and accrued expenses	491,654	615,815
Total current liabilities	561,199	654,953
Long term debt:
Notes payable - related party, net of discounts	240,973	120,508
Total Liabilities	802,172	775,461
Stockholders' equity:
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 345,000 shares issued and outstanding at September 30, 2020 and December 31, 2019	69	69
Common stock $0.0002 par value, 1,500,000,000 shares authorized; 204,450,642 and 193,521,506 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	40,890	38,704
Additional paid-in capital	7,353,503	6,135,885
Accumulated deficit	(6,748,236)	(5,494,193)
Total Stockholders' Equity	646,226	680,465
Total Liabilities and Stockholders' Equity	$ 1,448,398	$ 1,455,926

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	345,000	345,000
Preferred stock, shares outstanding (in shares)	345,000	345,000
Common stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Common stock, shares authorized (in shares)	1,500,000,000	1,500,000,000
Common stock, shares issued (in shares)	204,450,642	193,521,506
Common stock, shares outstanding (in shares)	204,450,642	193,521,506

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income:
Revenue
Expenses:
Research and development	37,197	25,623	117,187	77,740
General and administrative	316,376	868,556	780,491	1,211,810
Interest	80,531	41,209	357,615	230,011
Total expenses	434,104	935,388	1,255,293	1,519,561
Other income			1,250
Net loss	$ (434,104)	$ (935,388)	$ (1,254,043)	$ (1,519,561)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.002)	$ (0.013)	$ (0.006)	$ (0.022)
Weighted average shares outstanding, basic and diluted (in shares)	203,710,642	70,103,698	200,016,816	69,358,355

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	345,000	68,474,520
Balance at Dec. 31, 2018	$ 69	$ 13,695	$ 2,166,745	$ (3,639,808)	$ (1,459,299)
Net loss for the period				(298,323)	(298,323)
Common stock issued for liabilities (in shares)		199,017
Common stock issued for liabilities		$ 40	7,822		7,862
Balance (in shares) at Mar. 31, 2019	345,000	68,673,537
Balance at Mar. 31, 2019	$ 69	$ 13,735	2,174,567	(3,938,131)	(1,749,760)
Balance (in shares) at Dec. 31, 2018	345,000	68,474,520
Balance at Dec. 31, 2018	$ 69	$ 13,695	2,166,745	(3,639,808)	(1,459,299)
Notes payable converted to common stock
Net loss for the period					(1,519,561)
Stock options exchanged for common stock
Balance (in shares) at Sep. 30, 2019	345,000	70,190,699
Balance at Sep. 30, 2019	$ 69	$ 14,038	3,065,763	(5,159,369)	(2,079,499)
Balance (in shares) at Mar. 31, 2019	345,000	68,673,537
Balance at Mar. 31, 2019	$ 69	$ 13,735	2,174,567	(3,938,131)	(1,749,760)
Net loss for the period				(285,850)	(285,850)
Common stock issued for liabilities (in shares)		273,469
Common stock issued for liabilities		$ 54	11,138		11,192
Common stock issued for services (in shares)		972,668
Common stock issued for services		$ 195	29,496		29,691
Balance (in shares) at Jun. 30, 2019	345,000	69,919,674
Balance at Jun. 30, 2019	$ 69	$ 13,984	2,215,201	(4,223,981)	(1,994,727)
Net loss for the period				(935,388)	(935,388)
Options issued for compensation and services			840,500		840,500
Common stock issued for services (in shares)		271,025
Common stock issued for services		$ 54	10,062		10,116
Balance (in shares) at Sep. 30, 2019	345,000	70,190,699
Balance at Sep. 30, 2019	$ 69	$ 14,038	3,065,763	(5,159,369)	(2,079,499)
Balance (in shares) at Dec. 31, 2019	345,000	193,521,506
Balance at Dec. 31, 2019	$ 69	$ 38,704	6,135,885	(5,494,193)	680,465
Warrants issued			53,447		53,447
Notes payable converted to common stock (in shares)		9,129,136
Notes payable converted to common stock		$ 1,826	298,174		300,000
Beneficial converson feature of note payable			310,303		310,303
Net loss for the period				(530,307)	(530,307)
Balance (in shares) at Mar. 31, 2020	345,000	202,650,642
Balance at Mar. 31, 2020	$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Balance (in shares) at Dec. 31, 2019	345,000	193,521,506
Balance at Dec. 31, 2019	$ 69	$ 38,704	6,135,885	(5,494,193)	680,465
Notes payable converted to common stock					300,000
Net loss for the period					$ (1,254,043)
Exchange of stock options for common shares (in shares)					1,800,000
Stock options exchanged for common stock					$ 360
Balance (in shares) at Sep. 30, 2020	345,000	204,450,642
Balance at Sep. 30, 2020	$ 69	$ 40,890	7,353,503	(6,748,236)	646,226
Balance (in shares) at Mar. 31, 2020	345,000	202,650,642
Balance at Mar. 31, 2020	$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Warrants issued			23,692		23,692
Beneficial converson feature of note payable			191,839		191,839
Net loss for the period				(289,632)	(289,632)
Exchange of stock options for common shares (in shares)		900,000
Stock options exchanged for common stock		$ 180	(180)
Balance (in shares) at Jun. 30, 2020	345,000	203,550,642
Balance at Jun. 30, 2020	$ 69	$ 40,710	7,013,160	(6,314,132)	739,807
Warrants issued			31,454		31,454
Beneficial converson feature of note payable			235,296		235,296
Net loss for the period				(434,104)	(434,104)
Exchange of stock options for common shares (in shares)		900,000
Stock options exchanged for common stock		$ 180	(180)
Options issued for compensation and services			73,773		73,773
Balance (in shares) at Sep. 30, 2020	345,000	204,450,642
Balance at Sep. 30, 2020	$ 69	$ 40,890	$ 7,353,503	$ (6,748,236)	$ 646,226

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		64 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (434,104)	$ (530,307)	$ (935,388)	$ (298,323)	$ (1,254,043)	$ (1,519,561)	$ 6,748,236
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation					126	567
Amortization - patents					60,172	60,172
Amortization - debt discount					296,738	45,134
Options issued for services					73,773	724,631
Common stock issued for services						39,807
Change in:
Prepaid expenses					(89,579)	11,229
Deposits					2,315
Accounts payable and accrued liabilities					(124,160)	409,381
Net cash used in operating activities					(1,034,659)	(228,640)
Cash Flows from Financing Activities
Payments on insurance premium financing					(46,986)	(36,680)
Proceeds from debt and warrants issued					1,047,151	270,000
Net cash provided by financing activities					1,000,165	233,320
Net change in cash					(34,494)	4,680
Cash, beginning of period		58,149		$ 4,001	58,149	4,001
Cash, end of period	23,655		$ 8,681		23,655	8,681	$ 23,655
Supplemental Disclosure of Cash flow Information
Cash paid during the period for interest					50,271	2,921
Non-Cash Financing Activities
Notes payable converted to common stock		$ 300,000			300,000
Stock options exchanged for common stock					360
Options issued for accounts payable						115,869
Common stock issued to satisfy liabilities						19,054
Recognition of beneficial conversion feature					$ 737,437

Note 1 - Business Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 – Business Organization, Nature of Business and Basis of Presentation Nature of Business The Coretec Group Inc. (the “Group”) (formerly 3DIcon Corporation) ( “3DIcon” ) was incorporated on August 11, 1995, under the laws of the State of Oklahoma as First Keating Corporation. The articles of incorporation were amended on August 1, 2003 to change the name to 3DIcon Corporation. During 2001, First Keating Corporation began to focus on the development of its 360 -degree holographic technology. From January 1, 2001, 3DIcon's primary activity has been the raising of capital in order to pursue its goal of becoming a significant participant in the development, commercialization, and marketing of next generation 3D display technologies. Coretec Industries, LLC (“Coretec”), a wholly owned subsidiary of the Group (collectively the “Company”), was organized on June 2, 2015 in the state of North Dakota. Coretec is currently developing, testing, and providing new and/or improved technologies, products, and service solutions for energy-related industries including, but not limited to oil/gas, renewable energy, and distributed energy industries. Many of these technologies and products also have application for medical, electronic, photonic, display, and lighting markets among others. Early adoption of these technologies and products is anticipated in markets for energy storage (Li-ion batteries), renewable energy (BIPV), and electronics (Asset Monitoring). Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company's year-end audited consolidated financial statements and related footnotes included in the previously filed Form 10 -K, and in the opinion of management, reflects all adjustments necessary to present fairly the consolidated financial position of the Company. The consolidated results of operations for interim periods may not be indicative of the results which may be realized for the full year.

Note 2 - Going Concern and Management's Plans	9 Months Ended
Note 2 - Going Concern and Management's Plans	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 – Going Concern and Management's Plans The Company has realized a cumulative net loss of $6,748,236 for the period from its inception ( June 2, 2015) to September 30, 2020, has negative working capital of $359,144 and no revenues. The Company has insufficient revenue and capital commitments to fund the development of its planned products and pay operating expenses. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern for a year following the issuance of these condensed consolidated financial statements. The ability of the Company to continue as a going concern depends on the successful completion of the Company's capital raising efforts to fund the development of its planned products. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company's debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company's business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 3 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

– Summary of Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.

Long-Lived Assets

Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset

may

not

be recoverable. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company

first

compares undiscounted cash flows expected to be generated with that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is

not

recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and

third

-party independent appraisals, as considered necessary.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications apply only to the Statement of Operations and have

effect on the previously reported net loss.

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company:

Current assets and current liabilities

- The carrying value approximates fair value due to the short maturity of these items.

Notes payable -

The fair value of the Company's notes payable has been estimated by the Company based upon the liability's characteristics, including interest rates, embedded instruments and conversion discounts. The carrying value approximates fair value.

Beneficial Conversion Feature of Convertible Notes Payable

The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic

470

20,

Debt with Conversion and Other Options. The beneficial conversion feature of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a beneficial conversion feature related to the issuance of a convertible note when issued.

The beneficial conversion feature of a convertible note is credited to additional paid-in-capital. The intrinsic value is recorded in the condensed consolidated financial statements as a debt discount and such discount is amortized over the expected term of the convertible note and is charged to interest expense.

Earnings(Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

Diluted loss per common share is calculated the same as basic loss per common share for all periods presented because the exercise or conversion of the securities and other instruments would be anti-dilutive due to the net loss.

The following securities and other instruments to issue common stock are excluded from the calculation of weighted average dilutive common shares:

	September 30 ,
	2020		2019
Options		20,212,174		20,716,557
Warrants		1,770,000		61
Series A convertible preferred stock		115,000		115,000
Convertible debt		35,755,783		253,106,815
Total potentially dilutive shares		57,852,957		273,938,433

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did

not

identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note

Recent Accounting Pronouncements

The following is a summary of recent accounting pronouncements that are relevant to the Company:

January 2017,

the FASB issued ASU

2017

04,

Intangibles – Goodwill and Other (Topic

350

): Simplifying the Test for Goodwill Impairment

. This ASU simplifies the subsequent measurement of goodwill by eliminating Step

from the goodwill test. Under Step

an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, an entity should measure goodwill impairment and test by comparing the fair value of a reporting unity with its carrying amount. The Company adopted this standard effective

January 1, 2020

and will apply the standard on a prospective basis. The adoption of this standard did

not

have a material impact on the Company's consolidated financial position and results of operations.

August 2020,

the FASB issued ASU

2020

06,

Debt with Conversion and Other Options (Subtopic

470

) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic

815

This ASU simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. As a result, after adopting ASU

No.

2020

06,

the Company will

longer separately present the embedded conversion feature of its convertible debt within stockholders' equity and interest expense is expected to decrease due to the elimination of debt discount amortization. ASU

No.

2020

is effective for the Company in the

first

quarter of

2024,

with early adoption permitted for the Company in the

first

quarter of

2021,

and

may

be adopted using either a full or modified retrospective approach. The Company is currently evaluating the full effect adopting ASU

No.

2020

06,

including the quantitative impact, will have on its consolidated financial statements, including the timing and adoption approach.

Note 4 - Notes Payable

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Debt Disclosure [Text Block]

Note

– Notes Payable

	September 30,			December 31,
	2020			2019
Notes payable:
6.3% Insurance premium finance agreement due July 2020	$	-		$	39,138
3.8% Insurance premium finance agreement due June 2021		69,545			-

Notes payable - related party:
10% Promissory note due January 2024		1,175,000			475,000
Less:
Beneficial conversion feature		(773,317	)		(273,422	)
Warrants issued		(123,001	)		(59,108	)
Debt issue costs		(37,709	)		(21,962	)
Total notes payable - related party	$	240,973		$	120,508

6.3%

Insurance premium finance agreement, due

July 2020

The Company entered into an insurance financing agreement in

September 2019

totaling

$61,503.

The monthly payments under the agreement were due in

eleven

installments of

$5,591.

The Company fully paid off the note in the planned installments with the last payment in

July 2020.

% Insurance premium finance agreement, due

June 2021

The Company entered into an insurance financing agreement in

August 2020

totaling

$77,151.

The monthly payments under the agreement are due in

ten

installments of

$7,849.

The Company made the

first

installment payment in

September 2020.

10%

Promissory note due

January 2024,

net

October 4, 2019,

the Company entered into a Credit Agreement and related Promissory Note with DAF, the Lender. DAF is managed by Carlton James, Ltd, a UK-based company of which Simon Calton is the Chief Executive Officer. Mr. Calton is Co-Chairman of Coretec. The

10%

Promissory Note, in a principal amount of

$2,500,000,

is due

January 15, 2024

and has attached warrants to subscribe for and purchase

3,000,000

shares of common stock at an exercise price of

$0.052

per share. Under the terms of the Credit Agreement, DAF will fund the Promissory Note in

sixteen

(

) tranches in amounts of

$125,000

and

$175,000

per month beginning in

October 2019.

Interest is accrued monthly and paid in advance for the

first

months and thereafter principal and interest payments shall be paid monthly in equal amounts, amortized over a

-month period.

Under the terms of the Promissory Note, DAF has the right to elect to convert all or part of the Promissory Note at a price equal to

seventy

percent (

70%

) of the average closing price of the Company's common stock as reported on the over-the-counter quotation system on the OTC Markets during the

fifteen

(

) calendar days prior to the loan closing date of

October 4, 2019,

which calculates to

$0.0329

per share.

The embedded conversion option was deemed to be a beneficial conversion feature because the active conversion price was less than the commitment date market price of the common stock. Given the terms and related-party nature of the agreement, the commitment date was determined to be the date the funds are advanced to the Company and is limited to the funding value less other debt discounts (see below). A debt discount of

$737,437

and

$281,837

was recorded, with a corresponding credit to additional paid-in capital for the beneficial conversion feature for the

nine

months ended

September 30, 2020

and the year ended

December 31, 2019,

respectively. The debt discount will be amortized over the life of the debt and

$107,552

was amortized to interest expense during the

nine

months ended

September 30, 2020.

Under the terms of the DAF Credit Agreement, warrants to subscribe for and purchase

3,000,000

shares of common stock at an exercise price of

$0.052

per share are available to be issued to DAF. The warrants will be issued in amounts of

150,000

and

210,000

per month as the advance is received during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at

1.2

warrants for every

of funding. As of

September 30, 2020,

1,770,000

warrants have been granted under the terms of the DAF Credit Agreement. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants. The allocated cost of the warrants amounted to

$108,594

and

$60,593

during the

nine

months ended

September 30, 2020

and the year ended

December 31, 2019,

respectively, and is being amortized over the life of the debt.

$19,398

was amortized during the

nine

months ended

September 30, 2020.

Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of

of each advance and reimburse DAF for certain expenses in connection with the preparation, interpretation, performance and enforcement of the Credit Agreement. Those costs amounted to

$30,000

and

$22,767

for the

nine

months ended

September 30, 2020

and the year ended

December 31, 2019

and are being amortized over the life of the debt with

$6,080

being amortized during the

nine

months ended

September 30, 2020.

March 31, 2020,

under the terms of the Credit Agreement, DAF converted

$300,000

of the principle of the Promissory Note into

9,129,136

shares of common stock at

$0.0329

per share. A related charge of

$130,370

of the beneficial conversion feature was made to interest expense along with debt issue related charges of

$25,523

for the warrants and

$8,123

for the deferred cost at the time of the conversion.

Note 5 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note

– Commitments and Contingencies

Warrants

Under the terms of the DAF Credit Agreement, warrants to subscribe for and purchase

3,000,000

shares of common stock at an exercise price of

$0.052

per share are available to be issued to DAF. The warrants are being issued in amounts of

150,000

and

210,000

per month during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at

1.2

warrants for every

of funding. As of

September 30, 2020,

1,770,000

warrants have been granted under the terms of the DAF Credit Agreement. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrant.

Warrants Summary

The following table summarizes the Company's warrant activity during the

nine

months ended

September 30, 2020:

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, December 31, 2019

570,000

0.052

Granted

1,200,000

0.052

Outstanding, September 30, 2020

1,770,000

0.052

4.44

Options

Stock options for employees, directors or consultants that vest immediately, are valued at the date of award, which does

not

precede the approval date, and compensation cost is recognized in the period the options are vested. For options subject to future service conditions, compensation cost is recognized over the vesting period on a straight-line basis. Stock options generally become exercisable on the date of grant and expire based on the terms of each grant.

The estimated fair value of options for common stock granted is determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience.

The following table summarizes the Company's option activity during the

nine

months ended

September 30, 2020:

				Weighted Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, December 31, 2019		21,716,557		$	0.076
Expired		(4,383	)		52.50
Exchanged for common stock		(3,000,000	)		0.041
Granted		1,500,000			0.057
Outstanding, September 30, 2020		20,212,174		$	0.068		3.95	$	-

Exercisable, September 30, 2020		19,212,174		$	0.068		3.90	$	-

June 8, 2020,

the Board of Directors consented to a share exchange agreement with holders of

21,500,000

options awarded on

August 7, 2019.

The agreement allows for holders to exchange their options for rule

144

common stock at an exchange rate of

0.6

shares per

option. The modification of these options did

not

result in any additional compensation because there was

change in the fair value. As of

September 30, 2020,

3,000,000

options have been exchanged for

1,800,000

shares that were issued under the executed exchange agreement.

The following table summarizes the Company's options as of

September 30, 2020:

				Weighted
				Average
		Outstanding		Remaining		Exercisable
Exercise		Number of		Life		Number of
Price		Options		In Years		Options

$	0.041		19,000,000		3.88		19,000,000
$	0.065		1,000,000		4.75		-
$	0.240		208,160		6.47		208,160
$	70.260		3,449		1.75		3,449
$	420.000		565		0.62		565
Total			20,212,174		3.95		19,212,174

Litigation, Claims, and Assessments

The Company

may

be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently

not

expected to have a material impact on the Company's condensed consolidated financial statements. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Office Leases

and rent expenses

The Company had an amended office lease in Tulsa, Oklahoma that expired on

July 31, 2018.

The Company was on a month to month basis at

$1,980

per month under the terms of the Tulsa lease. The Company gave notice of termination of the Tulsa office lease and vacated the property on

June 23, 2020

and the security deposit has been refunded.

Additionally, on

December 3, 2019,

the Company signed a

one

-year office lease in Ann Arbor, Michigan commencing

January 1, 2020.

The remaining rent obligation on the Ann Arbor office is

$7,560

(

$1,260

per month) as of

September 30, 2020.

Rent expense for the operating leases was

$22,134

and

$17,820

for the

nine

months ended

September 30, 2020

and

2019,

respectively.

Supply Agreement

During

June 2020,

the Company entered into a supply agreement with Evonik Operations GmbH to purchase cyclohexasilane,

Si6H12

(CHS) for

$185,000

per

500

grams. The supply agreement is valid until

March 31, 2021.

The Company paid Evonik Operations GmbH

$92,500

July 20, 2020,

to initiate production of CHS, in accordance with the agreement.

Note 6 - Subsequent Events	9 Months Ended
Note 6 - Subsequent Events	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 6 – Subsequent Events Common stock issuance Subsequent to September 30, 2020, the company issued 500,000 shares to a consultant in connection with services provided. Securities Market On October 29, 2020, the Company moved the trading of its securities to the OTCQB, also known as the Venture Market, from OTC Pink market. The fees for listing on OTCQB markets is $12,000 per annum, with a one -time application fee of $2,500. The OTCQB market is the middle tier of the OTC Markets and consists of early-stage and developing U.S. and international companies. Conversion of convertible debt On October 30, 2020, DAF provided notice to convert $250,000 of debt at the stated conversion price of $0.0329 per share, resulting in an issuance of 7,598,784 shares.

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Property, Plant and Equipment, Policy [Policy Text Block]

Long-Lived Assets

Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset

may

not

be recoverable. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company

first

compares undiscounted cash flows expected to be generated with that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is

not

third

-party independent appraisals, as considered necessary.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

effect on the previously reported net loss.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company:

Current assets and current liabilities

- The carrying value approximates fair value due to the short maturity of these items.

Notes payable -

Debt Instrument, Convertible, Beneficial Conversion Feature [Policy Text Block]

Beneficial Conversion Feature of Convertible Notes Payable

470

20,

Earnings Per Share, Policy [Policy Text Block]

Earnings(Loss) Per Common Share

The following securities and other instruments to issue common stock are excluded from the calculation of weighted average dilutive common shares:

	September 30 ,
	2020		2019
Options		20,212,174		20,716,557
Warrants		1,770,000		61
Series A convertible preferred stock		115,000		115,000
Convertible debt		35,755,783		253,106,815
Total potentially dilutive shares		57,852,957		273,938,433

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did

not

identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The following is a summary of recent accounting pronouncements that are relevant to the Company:

January 2017,

the FASB issued ASU

2017

04,

Intangibles – Goodwill and Other (Topic

350

): Simplifying the Test for Goodwill Impairment

. This ASU simplifies the subsequent measurement of goodwill by eliminating Step

from the goodwill test. Under Step

January 1, 2020

and will apply the standard on a prospective basis. The adoption of this standard did

not

have a material impact on the Company's consolidated financial position and results of operations.

August 2020,

the FASB issued ASU

2020

06,

Debt with Conversion and Other Options (Subtopic

470

) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic

815

No.

2020

06,

the Company will

No.

2020

is effective for the Company in the

first

quarter of

2024,

with early adoption permitted for the Company in the

first

quarter of

2021,

and

may

be adopted using either a full or modified retrospective approach. The Company is currently evaluating the full effect adopting ASU

No.

2020

06,

including the quantitative impact, will have on its consolidated financial statements, including the timing and adoption approach.

Note 3 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	September 30 ,
	2020		2019
Options		20,212,174		20,716,557
Warrants		1,770,000		61
Series A convertible preferred stock		115,000		115,000
Convertible debt		35,755,783		253,106,815
Total potentially dilutive shares		57,852,957		273,938,433

Note 4 - Notes Payable (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	September 30,			December 31,
	2020			2019
Notes payable:
6.3% Insurance premium finance agreement due July 2020	$	-		$	39,138
3.8% Insurance premium finance agreement due June 2021		69,545			-

Notes payable - related party:
10% Promissory note due January 2024		1,175,000			475,000
Less:
Beneficial conversion feature		(773,317	)		(273,422	)
Warrants issued		(123,001	)		(59,108	)
Debt issue costs		(37,709	)		(21,962	)
Total notes payable - related party	$	240,973		$	120,508

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Note 5 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Warrant Activity [Table Text Block]

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, December 31, 2019

570,000

0.052

Granted

1,200,000

0.052

Outstanding, September 30, 2020

1,770,000

0.052

4.44

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

				Weighted Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, December 31, 2019		21,716,557		$	0.076
Expired		(4,383	)		52.50
Exchanged for common stock		(3,000,000	)		0.041
Granted		1,500,000			0.057
Outstanding, September 30, 2020		20,212,174		$	0.068		3.95	$	-

Exercisable, September 30, 2020		19,212,174		$	0.068		3.90	$	-

Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

				Weighted
				Average
		Outstanding		Remaining		Exercisable
Exercise		Number of		Life		Number of
Price		Options		In Years		Options

$	0.041		19,000,000		3.88		19,000,000
$	0.065		1,000,000		4.75		-
$	0.240		208,160		6.47		208,160
$	70.260		3,449		1.75		3,449
$	420.000		565		0.62		565
Total			20,212,174		3.95		19,212,174

Note 2 - Going Concern and Management's Plans (Details Textual) - USD ($)	3 Months Ended						9 Months Ended		64 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Net Income (Loss) Attributable to Parent, Total	$ (434,104)	$ (289,632)	$ (530,307)	$ (935,388)	$ (285,850)	$ (298,323)	$ (1,254,043)	$ (1,519,561)	$ 6,748,236
Working Capital Deficit	359,144						359,144		359,144
Revenue from Contract with Customer, Including Assessed Tax									$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Total potentially dilutive shares (in shares)	57,852,957	273,938,433
Options [Member]
Total potentially dilutive shares (in shares)	20,212,174	20,716,557
Warrant [Member]
Total potentially dilutive shares (in shares)	1,770,000	61
Series A Convertible Preferred Stock [Member]
Total potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
Total potentially dilutive shares (in shares)	35,755,783	253,106,815

Note 4 - Notes Payable (Details Textual)			1 Months Ended		9 Months Ended		12 Months Ended
Note 4 - Notes Payable (Details Textual)	Mar. 31, 2020 USD ($) $ / shares shares	Oct. 04, 2019 USD ($) $ / shares shares	Aug. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) $ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 0.052		$ 0.052
Amortization of Debt Discount (Premium)					$ 296,738	$ 45,134
Class of Warrant or Right, Issued Monthly (in shares) \| shares					1,200,000
Conversion of DAF Promissory Note into Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares	$ 0.0329
Amortization of Debt Discount (Premium)	$ 130,370
Allocated Cost of Warrants	25,523
Debt Agreement, Maximum Borrowing Capacity	$ 300,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	9,129,136
Deferred Costs, Total	$ 8,123
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares		3,000,000			3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.052			$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares) \| shares		1.2			1.2
Class of Warrant or Right, Issued During Period (in shares) \| shares					1,770,000
Allocated Cost of Warrants					$ 108,594		$ 60,593
Amortization Expense Associated With Warrants					$ 19,398
Warrant Issued in Connection With Credit Agreement [Member] \| Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares) \| shares		150,000			150,000
Warrant Issued in Connection With Credit Agreement [Member] \| Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares) \| shares		210,000			210,000
Six Point Three Percent Insurance Premium Finance Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage				6.30%		6.30%
Debt Instrument, Face Amount				$ 61,503		$ 61,503
Debt Instrument, Term (Month)				330 days
Debt Instrument, Periodic Payment, Total				$ 5,591
3.8% Insurance Premium Finance Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage			3.80%		3.80%
Debt Instrument, Face Amount			$ 77,151
Debt Instrument, Term (Month)			300 days
Debt Instrument, Periodic Payment, Total			$ 7,849
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.00%			10.00%		10.00%
Debt Agreement, Maximum Borrowing Capacity		$ 2,500,000
Debt Instrument, Number of Tranches		16
Debt Instrument, Period of Monthly Advance Interest Payments (Month)		1 year
Debt Instrument, Period Following Advance Interest Payments (Month)		3 years
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		70.00%
Debt Instrument, Convertible, Threshold Trading Days		15
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 0.0329
Debt Instrument, Unamortized Discount, Total					$ 737,437		$ 281,837
Amortization of Debt Discount (Premium)					107,552
Line of Credit Facility, Commitment Fee Percentage		3.00%
Line of Credit Facility, Commitment Fee and Debt-related Expenses to Be Amortized					30,000		$ 22,767
Amortization Associated With Commitment Fee					$ 6,080
Credit Agreement And Note [Member] \| Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 125,000
Credit Agreement And Note [Member] \| Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 175,000

Note 4 - Notes Payable - Schedule of Debt (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Notes payable	$ 69,545	$ 39,138
Notes Payable, Related Parties	240,973	120,508
Six Point Zero Five Percent Insurance Premium Finance Agreement, Due July 2019 [Member]
Notes payable		39,138
3.8% Insurance Premium Finance Agreement [Member]
Notes payable	69,545
Credit Agreement And Note [Member]
10% Promissory note due January 2024	1,175,000	475,000
Beneficial conversion feature	(773,317)	(273,422)
Warrants issued	(123,001)	(59,108)
Debt issue costs	$ (37,709)	$ (21,962)

Note 4 - Notes Payable - Schedule of Debt (Details) (Parentheticals)	Sep. 30, 2020	Aug. 31, 2020	Dec. 31, 2019	Oct. 04, 2019
Six Point Zero Five Percent Insurance Premium Finance Agreement, Due July 2019 [Member]
Interest rate	6.30%		6.30%
3.8% Insurance Premium Finance Agreement [Member]
Interest rate	3.80%	3.80%
Credit Agreement And Note [Member]
Interest rate	10.00%		10.00%	10.00%

Note 5 - Commitments and Contingencies (Details Textual)				9 Months Ended
	Jul. 20, 2020 USD ($)	Jun. 08, 2020 shares	Oct. 04, 2019 $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Dec. 31, 2019 $ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 0.052		$ 0.052
Class of Warrant or Right, Issued Monthly (in shares)				1,200,000
Share Exchange Agreement, Number of Options Authorized (in shares)		21,500,000
Share Exchange Agreement, Exchange Ratio		0.6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)				3,000,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares (in shares)				1,800,000
Lessee, Operating Lease, Liability, to be Paid, Total \| $				$ 7,560
Operating Lease, Expense \| $				22,134	$ 17,820
Evonik Operations GmbH [Member]
Purchase Obligation, Total \| $				185,000
Payments for Research and Development, Supply Agreement \| $	$ 92,500
Tulsa, Oklahoma [Member]
Operating Leases, Rent Expense, Monthly \| $				1,980
Ann Arbor, Michigan [Member]
Operating Leases, Rent Expense, Monthly \| $				$ 1,260
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,000,000	3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares			$ 0.052	$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)			1.2	1.2
Class of Warrant or Right, Issued During Period (in shares)				1,770,000
Warrant Issued in Connection With Credit Agreement [Member] \| Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			150,000	150,000
Warrant Issued in Connection With Credit Agreement [Member] \| Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			210,000	210,000

Note 5 - Commitments and Contingencies - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Outstanding, number of warrants (in shares) \| shares	570,000
Outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0.052
Granted, number of warrants (in shares) \| shares	1,200,000
Granted, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0.052
Outstanding, number of warrants (in shares) \| shares	1,770,000
Outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0.052
Outstanding, weighted-average remaining life (Year)	4 years 160 days
Outstanding, aggregate intrinsic value \| $

Note 5 - Commitments and Contingencies - Option Activity (Details)	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Exchanged for common stock (in shares)	(3,000,000)
Granted, Shares (in shares)	1,500,000
Granted, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0.057
Share-based Payment Arrangement, Option [Member]
Outstanding, Shares (in shares)	21,716,557
Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0.076
Outstanding, Weighted Average Remaining Life (Year)
Expired, Shares (in shares)	(4,383)
Expired, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 52.50
Exchanged for common stock (in shares)	(3,000,000)
Exchanged for common stock, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0.041
Outstanding, Shares (in shares)	20,212,174
Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0.068
Outstanding, Weighted Average Remaining Life in Years (Year)	3 years 346 days
Outstanding, Aggregate intrinsic value \| $
Exercisable, Shares (in shares)	19,212,174
Exercisable, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0.068
Exercisable, Weighted Average Remaining Life (Year)	3 years 328 days
Exercisable, Aggregate intrinsic value \| $

Note 5 - Commitments and Contingencies - Shares Authorized Under Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Option Outstanding, Number Of Options (in shares)	20,212,174
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 346 days
Option Exercisable, Number Of Options (in shares)	19,212,174
Option Exercisable, Number Of Options (in shares)	19,212,174
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	19,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 321 days
Option Exercisable, Number Of Options (in shares)	19,000,000
Option Exercisable, Number Of Options (in shares)	19,000,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 273 days
Option Exercisable, Number Of Options (in shares)
Option Exercisable, Number Of Options (in shares)
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.24
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	6 years 171 days
Option Exercisable, Number Of Options (in shares)	208,160
Option Exercisable, Number Of Options (in shares)	208,160
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 70.26
Option Outstanding, Number Of Options (in shares)	3,449
Option Exercisable, Weighted Average Remaining Life In Years (Year)	1 year 273 days
Option Exercisable, Number Of Options (in shares)	3,449
Option Exercisable, Number Of Options (in shares)	3,449
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 420
Option Outstanding, Number Of Options (in shares)	565
Option Exercisable, Weighted Average Remaining Life In Years (Year)	226 days
Option Exercisable, Number Of Options (in shares)	565
Option Exercisable, Number Of Options (in shares)	565

Note 6 - Subsequent Events (Details Textual) - USD ($)				1 Months Ended
Note 6 - Subsequent Events (Details Textual) - USD ($)	Oct. 30, 2020	Oct. 29, 2020	Mar. 31, 2020	Nov. 12, 2020
Conversion of DAF Promissory Note into Common Stock [Member]
Debt Agreement, Maximum Borrowing Capacity			$ 300,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.0329
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			9,129,136
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)				500,000
Annual Fees for Listing on Market		$ 12,000
Application Fee for Listing on Market		$ 2,500
Subsequent Event [Member] \| Conversion of DAF Promissory Note into Common Stock [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 250,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.0329
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	7,598,784